Evidence map›Paper›PMID 36027558›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Hope S Rugo, Aditya Bardia, Frederik Marmé, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo and 6 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03901339 (Phase 3 Study of Sacituzumab Govitecan), which is not on this map. Cited by 185 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
185citing papers in PubMed, 12 pooled it
40.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03901339 phase3completednot on this map

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens

TypeinterventionalSponsorGilead SciencesRan2019 to 2023Enrolled543ConditionsMetastatic Breast CancerArmsSacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
3 · Its place in the literature

Who cites it

185 citing papers in PubMed, 12 syntheses or guidelines pooled it, 282 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Guideline
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Sacituzumab govitecan in HRNature medicine · 2024
    Trial
  19. Trial
  20. Trial

125 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 5 countries.

Hope S RugoDepartment of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.ORCID 0000-0001-6710-4814
Aditya BardiaMedical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-4885-1157
Frederik MarméMedical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Heidelberg, Germany.ORCID 0000-0002-6591-3367
Javier CortesMedical Oncology Department, International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Madrid and Barcelona, Spain.ORCID 0000-0001-7623-1583
Peter SchmidBarts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-9817-5228
Delphine LoiratMedical Oncology Department and D3i, Institut Curie, Paris, France.
Olivier TrédanMedical Oncology Department, Centre Léon Bérard, Lyon, France.ORCID 0000-0001-5881-9383
Eva CiruelosMedical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0002-2796-1042
Florence DalencInstitut Claudius Regaud, IUCT-Oncopole, Toulouse, France.
Patricia Gómez PardoHospital Universitari Vall D'Hebron, Barcelona, Spain.ORCID 0000-0002-8011-634X
Komal L JhaveriMemorial Sloan-Kettering Cancer Center, New York, NY.
Rosemary DelaneyDepartment of Clinical Development, Gilead Sciences Inc, Foster City, CA.
Olivia FuDepartment of Global Patient Safety, Gilead Sciences Inc, Foster City, CA.
Lanjia LinDepartment of Biostatistics, Gilead Sciences Inc, Foster City, CA.
Wendy VerretDepartment of Clinical Development, Gilead Sciences Inc, Foster City, CA.
Sara M TolaneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-5940-8671
Gilead Sciences (United States) · USCentre Léon Bérard · FRDana-Farber Cancer Institute · USHarvard University · USHeidelberg University · DEHospital Universitario 12 De Octubre · ESInstitut Claudius Regaud · FRInstitut Curie · FRMemorial Sloan Kettering Cancer Center · USQueen Mary University of London · GBUniversidad Europea de Madrid · ESUniversity of California, San Francisco · USVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) endocrine-resistant metastatic breast cancer is treated with sequential single-agent chemotherapy with poor outcomes. Sacituzumab govitecan (SG) is a first-in-class antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer.

methodsIn this global, randomized, phase III study, SG was compared with physician's choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in endocrine-resistant, chemotherapy-treated HR+/HER2- locally recurrent inoperable or metastatic breast cancer. The primary end point was progression-free survival (PFS) by blinded independent central review.

resultsPatients were randomly assigned to receive SG (n = 272) or chemotherapy (n = 271). The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease. Primary end point was met with a 34% reduction in risk of progression or death (hazard ratio, 0.66 [95% CI, 0.53 to 0.83;

conclusionSG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR+/HER2- advanced breast cancer and limited treatment options.

Indexed as

Breast NeoplasmsImmunoconjugatesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinCapecitabineCyclin-Dependent Kinase 4Erb-b2 Receptor Tyrosine KinasesFemaleHumansIrinotecanMiddle AgedVinorelbineAntibodies, Monoclonal, HumanizedCamptothecinCapecitabineCyclin-Dependent Kinase 4ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesIrinotecansacituzumab govitecanVinorelbine

Identifiers

PMID36027558
OpenAlexW4293795388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.